| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-114 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 具体变动情况如下： 1 上海皓元医药股份有限公司 关于控股股东可转债持有比例变动达到 10%的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、可转债配售情况 经中国证券监督管理委员会《关于同意上海皓元医药股份有限公司向不特 定对象发行可转换公司债券注册的批复》（证监许可[2024]1289 号）同意，上海 皓元医药股份有限公司（以下简称"公司"、"本公司"）于 2024 年 11 月 28 日 向不特定对象发行 822.35 万张可转换公司债券，每张面值为人民币 100 元，发 行总额 82,235.00 万元，期限 6 年。 经上海证券交易所自律监管决定书[2024]168 号文同意，公司本次可转换公 司债券于 2024 年 12 月 19 日起在上海证券交易所上市交易，债券简称"皓元转 债"，债券代码"118051"。 公司 ...

Group 1 - The core point of the news is that Haoyuan Pharmaceutical's stock price dropped by 5.24% to 81.00 CNY per share, with a trading volume of 237 million CNY and a turnover rate of 1.35%, resulting in a total market capitalization of 17.18 billion CNY [1] - Haoyuan Pharmaceutical, established on September 30, 2006, and listed on June 8, 2021, specializes in the discovery of small molecule drugs, including the research and development of molecular building blocks and tool compounds, as well as the process development and production technology improvement of active pharmaceutical ingredients and intermediates [1] - The company's main business revenue composition includes molecular building blocks, tool compounds, and biochemical reagents at 68.97%, with product sales contributing 63.42%, active pharmaceutical ingredients and intermediates at 30.46%, technical services at 5.55%, and other supplementary services at 0.57% [1] Group 2 - From the perspective of fund holdings, Haoyuan Pharmaceutical is a top ten holding of the Hengsheng Qianhai Fund, specifically in the Hengsheng Qianhai Hong Kong-Shenzhen Emerging Industry Selected Mixed Fund (004332), which held 24,600 shares, accounting for 2.1% of the fund's net value, with an estimated floating loss of approximately 110,200 CNY [2] - The Hengsheng Qianhai Hong Kong-Shenzhen Emerging Industry Selected Mixed Fund (004332) was established on April 1, 2017, with a latest scale of 56.68 million CNY, achieving a year-to-date return of 43.74% and a one-year return of 40.63% [2] - The fund manager, Xing Cheng, has been in position for 3 years and 203 days, with the fund's total asset size at 252 million CNY, achieving the best return of 87.69% and the worst return of -29.15% during his tenure [3]

Core Viewpoint - The performance of the Zhongzheng 1000 ETF Enhanced (561280) has shown a slight decline at the opening, with a reported drop of 0.33% to 1.517 yuan, indicating market volatility and investor sentiment towards the fund's holdings [1] Group 1: Fund Performance - The Zhongzheng 1000 ETF Enhanced (561280) has a performance benchmark based on the Zhongzheng 1000 Index return [1] - Since its establishment on August 31, 2023, the fund has achieved a return of 52.12% [1] - Over the past month, the fund has recorded a return of 5.46% [1] Group 2: Major Holdings - Key stocks in the fund include Xiangdian Co., which opened down 0.55%, and Haoyuan Pharmaceutical, which fell by 1.15% [1] - Other notable stocks include Xinqianglian, which rose by 0.43%, and Chujian New Materials, which increased by 0.40% [1] - The fund also holds shares in Nanwei Software, Zhenlei Technology, and Hongsoft Technology, with varying performance [1]

Core Insights - On October 9, Haoyuan Pharmaceutical's stock rose by 3.49%, with a trading volume of 508 million yuan [1] - The company reported a financing buy-in of 70.22 million yuan and a net financing buy-in of 3.93 million yuan on the same day [1] - As of October 9, the total balance of margin trading for Haoyuan Pharmaceutical was 416 million yuan, indicating a high level of trading activity [1] Financing Summary - On October 9, Haoyuan Pharmaceutical had a financing buy-in of 70.22 million yuan, with a current financing balance of 414 million yuan, representing 2.29% of its market capitalization [1] - The financing balance is above the 90th percentile of the past year, indicating a high level of investor interest [1] Short Selling Summary - On October 9, Haoyuan Pharmaceutical repaid 4,660 shares in short selling and sold 3,000 shares, amounting to 256,400 yuan at the closing price [1] - The remaining short selling volume was 15,000 shares, with a short selling balance of 1.28 million yuan, which is above the 70th percentile of the past year [1] Company Overview - Haoyuan Pharmaceutical, established on September 30, 2006, is located in Shanghai and specializes in the discovery of small molecule drugs, including the development of molecular building blocks and tool compounds [2] - The company's main business revenue composition includes 68.97% from molecular building blocks, tool compounds, and biochemical reagents, with product sales contributing 63.42% [2] - As of September 19, the number of shareholders increased by 17.93% to 12,800, with an average of 16,527 circulating shares per person, a decrease of 12.82% [2] Financial Performance - For the first half of 2025, Haoyuan Pharmaceutical achieved a revenue of 1.311 billion yuan, representing a year-on-year growth of 24.20% [2] - The net profit attributable to shareholders was 152 million yuan, showing a significant year-on-year increase of 115.55% [2] Dividend Information - Since its A-share listing, Haoyuan Pharmaceutical has distributed a total of 143 million yuan in dividends, with 103 million yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder, holding 6.2611 million shares, an increase of 329,200 shares from the previous period [3] - The fund "China Europe Medical Health Mixed A" ranked fifth among circulating shareholders, holding 6.1185 million shares, a decrease of 2.7776 million shares from the previous period [3]

Core Points - The announcement details the conversion results of the convertible bonds issued by Shanghai Haoyuan Pharmaceutical Co., Ltd. and the changes in share capital as of September 30, 2025 [1][2] Group 1: Convertible Bond Conversion Status - As of September 30, 2025, a total of RMB 464,000 of "Haoyuan Convertible Bonds" has been converted into company shares, resulting in 11,412 shares, which accounts for 0.0054% of the total shares before conversion [2][6] - The amount of "Haoyuan Convertible Bonds" that has not been converted as of September 30, 2025, is RMB 821,886,000, representing 99.94% of the total issuance [2][6] - During the period from July 1, 2025, to September 30, 2025, RMB 414,000 of "Haoyuan Convertible Bonds" was converted into shares, totaling 10,190 shares, which is 0.0048% of the total shares before conversion [2][6] Group 2: Convertible Bond Issuance Overview - The company issued 8,223,500 convertible bonds on November 28, 2024, with a total value of RMB 82,235,000 and a maturity of 6 years [3] - The bonds were listed for trading on December 19, 2024, under the name "Haoyuan Convertible Bonds" with the code "118051" [3] - The initial conversion price was set at RMB 40.73 per share, with adjustments made due to various corporate actions [3][4][5] Group 3: Share Capital Changes - The total share capital of the company was reduced by 47,725 shares on July 4, 2025, due to the cancellation of shares related to performance commitments [7] - The company completed the registration of 648,570 shares from the 2022 restricted stock incentive plan on July 8, 2025, which were then listed for trading [8] - Additional shares from the 2023 restricted stock incentive plan were also registered and listed for trading in subsequent months [8]

Market Overview - On October 9, the medical services sector rose by 0.91%, with Jiuzhou Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3933.97, up 1.32%, while the Shenzhen Component Index closed at 13725.56, up 1.47% [1] Top Gainers in Medical Services - Jiuzhou Pharmaceutical (603456) closed at 20.61, up 5.96% with a trading volume of 418,800 shares and a transaction value of 844 million [1] - Meinian Health (002044) closed at 5.20, up 4.63% with a trading volume of 1,667,200 shares and a transaction value of 871 million [1] - Heyuan Biotechnology (688238) closed at 8.20, up 4.19% with a trading volume of 344,500 shares and a transaction value of 285 million [1] - Sanbo Brain Science (301293) closed at 60.80, up 4.02% with a trading volume of 110,100 shares and a transaction value of 660 million [1] - Haoyuan Pharmaceutical (688131) closed at 85.48, up 3.49% with a trading volume of 59,800 shares and a transaction value of 508 million [1] Top Losers in Medical Services - Digital Human (920670) closed at 14.21, down 8.73% with a trading volume of 68,800 shares and a transaction value of 96.92 million [2] - ST Biological (000504) closed at 9.07, down 4.02% with a trading volume of 46,100 shares and a transaction value of 42.42 million [2] - Baicheng Pharmaceutical (301096) closed at 57.99, down 3.35% with a trading volume of 32,600 shares and a transaction value of 191 million [2] Fund Flow Analysis - The medical services sector experienced a net outflow of 308 million from institutional investors, while retail investors saw a net inflow of 348 million [2] - The net outflow from retail investors amounted to 40.85 million [2] Individual Stock Fund Flow - Aier Eye Hospital (300015) had a net inflow of 283 million from institutional investors, while retail investors experienced a net outflow of 137 million [3] - Sanbo Brain Science (301293) saw a net inflow of 63.69 million from institutional investors, with retail investors facing a net outflow of 45.84 million [3] - Jiuzhou Pharmaceutical (603456) had a net inflow of 53.54 million from institutional investors, while retail investors faced a net outflow of 63.40 million [3]

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-113 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 可转债转股结果暨股份变动公告 未转股可转债情况：截至 2025 年 9 月 30 日，"皓元转债"尚未转股的 金额为 821,886,000 元，占"皓元转债"发行总量的 99.94%。 本季度转股情况：自 2025 年 7 月 1 日至 2025 年 9 月 30 日期间，"皓元 转债"共有人民币 414,000 元转换为公司股票，转股数量为 10,190 股，占"皓 元转债"转股前公司已发行股份总额的 0.0048%。 一、可转债发行上市概况 经中国证券监督管理委员会《关于同意上海皓元医药股份有限公司向不特 定对象发行可转换公司债券注册的批复》（证监许可[2024]1289 号）同意，上海 皓元医药股份有限公司（以下简称"公司"、"本公司"）于 2024 年 11 月 28 日 向不特定对象发行 822.35 万张可转换公司债券，每张面值为人民币 100 元，发 行总额 82,235.00 万元 ...

Group 1 - The CRO sector led the market with a rise of 3.5% on September 30 [1] - Haoyuan Pharmaceutical increased by 6.58% [1] - WuXi AppTec rose by 6.21% [1] - Boteng Co., Ltd. saw an increase of 4.99% [1] - MediSci and Northgrip, as well as Chengda Pharmaceutical, all experienced gains exceeding 4% [1]

Group 1 - The core viewpoint of the news is that Haoyuan Pharmaceutical has seen a stock price increase of 5.07% as of September 30, reaching 81.60 CNY per share, with a total market capitalization of 17.307 billion CNY [1] - Haoyuan Pharmaceutical, established on September 30, 2006, specializes in the research and development of molecular building blocks and tool compounds in the small molecule drug discovery field, as well as the process development and production technology improvement of active pharmaceutical ingredients (APIs) and intermediates [1] - The company's main business revenue composition includes molecular building blocks, tool compounds, and biochemical reagents at 68.97%, with product sales contributing 63.42%, APIs and intermediates at 30.46%, technical services at 5.55%, and other sources at 0.57% [1] Group 2 - From the perspective of fund holdings, Haoyuan Pharmaceutical is a top ten holding of the Hengsheng Qianhai Fund, specifically in the Hengsheng Qianhai Hong Kong-Shenzhen Emerging Industry Selected Mixed Fund (004332), which held 24,600 shares, accounting for 2.1% of the fund's net value [2] - The fund has achieved a year-to-date return of 39.78%, ranking 2105 out of 8167 in its category, and a one-year return of 45.37%, ranking 2370 out of 8010 [2] Group 3 - The fund manager of Hengsheng Qianhai Hong Kong-Shenzhen Emerging Industry Selected Mixed Fund (004332) is Xing Cheng, who has been in the position for 3 years and 193 days, with the fund's total asset size at 252 million CNY [3] - During Xing Cheng's tenure, the best fund return was 87.69%, while the worst return was -29.15% [3]

Core Viewpoint - The company announces the suspension of the conversion of its convertible bonds "Hao Yuan Convertible Bonds" during the implementation of the 2025 semi-annual profit distribution plan, which includes a cash dividend of 0.80 yuan per 10 shares [2][3]. Summary by Sections 1. Securities Suspension and Resumption - The "Hao Yuan Convertible Bonds" will stop conversion from October 13, 2025, until the equity registration date for the profit distribution [2][4]. - The bonds will resume conversion on the first trading day after the equity registration date [4]. 2. Profit Distribution Plan - The company will distribute a cash dividend of 0.80 yuan (including tax) for every 10 shares based on the total share capital registered on the equity registration date [3]. - The distribution plan does not include bonus shares or capital reserve conversion into share capital [3]. - The company will adjust the conversion price of the "Hao Yuan Convertible Bonds" according to the terms outlined in the prospectus after the profit distribution [3]. 3. Additional Information - Detailed information regarding the "Hao Yuan Convertible Bonds" can be found in the prospectus disclosed on November 26, 2024 [5].